Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Journal of Hematology & Oncology, 06/12/2012

The results indicate that relapse rate can be reduced and diseasefree survival (DFS) may be improved in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) patients with imatinib maintenance therapy after HCT. BCR–ABL monitoring by quantitative reverse–transcription polymerase chain reaction (qRT–PCR) can guide maintenance therapy with imatinib including initiation time and treatment duration after allogeneic hematopoietic stem cell transplantation (allo–HCT)

Print Article Summary